SCHEMBL89583

SCHEMBL89583

CCOCCN1C(=O)C(C)(C)Oc2ccc(NC3CC3)cc21

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.45
POLB P06746 3/20 0.45
GAA P10253 1/20 0.45
KMT2A Q03164 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MEN1 O00255 1/20 0.44
HPGD P15428 1/20 0.42
MAPT P10636 1/20 0.40
RECQL P46063 1/20 0.40
USP2 O75604 1/20 0.40
ALOX15 P16050 1/20 0.40
REN P00797 2/20 0.39
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL90732 0.93 ALDH1A1 (0.44) ALDH1A1POLBGAAKMT2ASMN1; SMN2
SCHEMBL90232 0.89 ALDH1A1 (0.48) ALDH1A1POLBGAAKMT2ASMN1; SMN2
SCHEMBL90354 0.87 ALDH1A1 (0.50) ALDH1A1POLBGAAKMT2ASMN1; SMN2
SCHEMBL90462 0.85 REN (0.51) ALDH1A1POLBGAAKMT2ASMN1; SMN2
SCHEMBL90317 0.85 ALDH1A1 (0.44) ALDH1A1POLBGAAKMT2ASMN1; SMN2
SCHEMBL8235590 0.85 ALDH1A1 (0.44) ALDH1A1POLBGAAKMT2ASMN1; SMN2
SCHEMBL89662 0.84 REN (0.48) ALDH1A1POLBGAAKMT2ASMN1; SMN2
SCHEMBL90713 0.83 ALDH1A1 (0.44) ALDH1A1POLBGAAKMT2ASMN1; SMN2
SCHEMBL15087905 0.83 ALDH1A1 (0.44) ALDH1A1POLBGAAKMT2ASMN1; SMN2
SCHEMBL89967 0.82 ALDH1A1 (0.44) ALDH1A1POLBGAAKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2420491-B1 3 , 5-SUBSTITUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS NOVARTIS AG (CH) 2013-07-03 EP disclosed
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
EP-2420491-A1 3 , 5-substitued piperidine compounds as renin inhibitors Novartis AG (CH) 2012-02-22 EP disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed
WO-2007077005-A1 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS NOVARTIS AG (CH) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192148-A1 Organic Compounds REN, ACE, AGTR1 ALDH1A1 38/4885POLB 589/4885GAA 309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.